Innova Biosciences boosts Lightning-Link antibody labelling tech

By Staff Reporter

- Last updated on GMT


Related tags Antibody

The Sygnis subsidiary has extended its antibody labelling service to allow for scalability and bulk production of antibodies.

The Lightning-Link platform – marketed by Innova Biosciences – is now available in volumes from 10µg to 100mg in single reaction vials.

“For antibody manufacturers that have fixed internal processes for conjugation, bulk supply of ultra-high quality raw materials and labels that are used in the Lightning-Link kits are also available,” ​said the firm.

The platform can be used in research & development (R&D) and drug discovery, and according to Innova Biosciences is the most efficient method of labelling antibodies or proteins on the market – with only 30 seconds hands-on time.

CEO Alastair Carrington said the extended capabilities will benefit both small and large-scale antibody manufacturers. 

“Access to Lightning-Link technology will enable manufacturers to dramatically increase their conjugate portfolios, whilst retaining batch-to-batch consistency,” ​he added.

Last month, US Biological announced​ an antibody labelling deal with Innova Biosciences’ Lightning-Link technology.

Related news

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 21-Feb-2023 | Product Brochure

Deliver safe and stable products to your patients with the help of Catalent Biologics' Limoges, France site, a European Center of Excellence for early-phase...

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Related suppliers

Follow us


View more